tiprankstipranks
Arcutis Biotherapeutics Inc (ARQT)
NASDAQ:ARQT
US Market
ARQT
Arcutis Biotherapeutics
RESEARCH TOOLSreports
Want to see ARQT full AI Analyst Report?

Arcutis Biotherapeutics (ARQT) Stock Forecast & Price Target

983 Followers
See the Price Targets and Ratings of:

ARQT Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Arcutis
Biotherapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ARQT Stock 12 Month Forecast

Average Price Target

$36.57
▲(33.72% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Arcutis Biotherapeutics in the last 3 months. The average price target is $36.57 with a high forecast of $40.00 and a low forecast of $34.00. The average price target represents a 33.72% change from the last price of $27.35.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","20":"$20","27":"$27","34":"$34","41":"$41"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.57142857142857,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$36.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,20,27,34,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.86,27.87076923076923,28.88153846153846,29.892307692307693,30.903076923076924,31.913846153846155,32.924615384615386,33.93538461538461,34.94615384615385,35.956923076923076,36.96769230769231,37.97846153846154,38.98923076923077,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.86,27.607032967032968,28.354065934065932,29.1010989010989,29.848131868131865,30.595164835164834,31.342197802197802,32.08923076923077,32.83626373626373,33.5832967032967,34.33032967032967,35.07736263736264,35.824395604395605,{"y":36.57142857142857,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.86,27.409230769230767,27.95846153846154,28.507692307692306,29.056923076923077,29.606153846153845,30.155384615384616,30.704615384615384,31.253846153846155,31.803076923076922,32.35230769230769,32.901538461538465,33.45076923076923,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.29,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.76,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.31,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.37,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.04,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.57,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.76,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.1,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.35,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.47,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.84,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.86,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$40.00Average Price Target$36.57Lowest Price Target$34.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on ARQT
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$34
Buy
24.31%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (NASDAQ: ARQT) and Biohaven Ltd. (NYSE: BHVN)
Needham Analyst forecast on ARQT
Serge Belanger
Needham
Needham
$40
Buy
46.25%
Upside
Assigned
08/06/26
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Arcutis Biotherapeutics (NASDAQ: ARQT) and Agilon Health (NYSE: AGL)
Mizuho Securities Analyst forecast on ARQT
Uy Ear
Mizuho Securities
Mizuho Securities
$35→$36
Buy
31.63%
Upside
Reiterated
08/06/26
Arcutis Biotherapeutics (ARQT) Gets a Buy from Mizuho Securities
Morgan Stanley Analyst forecast on ARQT
Judah Frommer
Morgan Stanley
Morgan Stanley
$34→$38
Buy
38.94%
Upside
Assigned
08/06/26
Morgan Stanley Sticks to Their Buy Rating for Arcutis Biotherapeutics (ARQT)
TD Cowen Analyst forecast on ARQT
Tyler Van Buren
TD Cowen
TD Cowen
$35
Buy
27.97%
Upside
Reiterated
08/05/26
Arcutis (ARQT): Strong Zoryve Outperformance and Raised 2026 Sales Outlook Underscore Buy Rating
Guggenheim Analyst forecast on ARQT
Seamus Fernandez
Guggenheim
Guggenheim
$35→$38
Buy
38.94%
Upside
Assigned
08/05/26
Arcutis Biotherapeutics price target raised to $38 from $35 at GuggenheimArcutis Biotherapeutics price target raised to $38 from $35 at Guggenheim
Jefferies Analyst forecast on ARQT
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$35
Buy
27.97%
Upside
Reiterated
07/09/26
Arcutis Biotherapeutics (ARQT) Receives a Buy from Jefferies
Goldman Sachs Analyst forecast on ARQT
Richard Law CFA
Goldman Sachs
Goldman Sachs
$29→$33
Hold
20.66%
Upside
Reiterated
02/27/26
Analysts Conflicted on These Healthcare Names: Arcutis Biotherapeutics (NASDAQ: ARQT), DENTSPLY SIRONA (NASDAQ: XRAY) and Edgewise Therapeutics (NASDAQ: EWTX)
BTIG Analyst forecast on ARQT
Kambiz Yazdi
BTIG
BTIG
$31
Buy
13.35%
Upside
Reiterated
01/15/26
BTIG Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on ARQT
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$34
Buy
24.31%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (NASDAQ: ARQT) and Biohaven Ltd. (NYSE: BHVN)
Needham Analyst forecast on ARQT
Serge Belanger
Needham
Needham
$40
Buy
46.25%
Upside
Assigned
08/06/26
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Arcutis Biotherapeutics (NASDAQ: ARQT) and Agilon Health (NYSE: AGL)
Mizuho Securities Analyst forecast on ARQT
Uy Ear
Mizuho Securities
Mizuho Securities
$35→$36
Buy
31.63%
Upside
Reiterated
08/06/26
Arcutis Biotherapeutics (ARQT) Gets a Buy from Mizuho Securities
Morgan Stanley Analyst forecast on ARQT
Judah Frommer
Morgan Stanley
Morgan Stanley
$34→$38
Buy
38.94%
Upside
Assigned
08/06/26
Morgan Stanley Sticks to Their Buy Rating for Arcutis Biotherapeutics (ARQT)
TD Cowen Analyst forecast on ARQT
Tyler Van Buren
TD Cowen
TD Cowen
$35
Buy
27.97%
Upside
Reiterated
08/05/26
Arcutis (ARQT): Strong Zoryve Outperformance and Raised 2026 Sales Outlook Underscore Buy Rating
Guggenheim Analyst forecast on ARQT
Seamus Fernandez
Guggenheim
Guggenheim
$35→$38
Buy
38.94%
Upside
Assigned
08/05/26
Arcutis Biotherapeutics price target raised to $38 from $35 at GuggenheimArcutis Biotherapeutics price target raised to $38 from $35 at Guggenheim
Jefferies Analyst forecast on ARQT
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$35
Buy
27.97%
Upside
Reiterated
07/09/26
Arcutis Biotherapeutics (ARQT) Receives a Buy from Jefferies
Goldman Sachs Analyst forecast on ARQT
Richard Law CFA
Goldman Sachs
Goldman Sachs
$29→$33
Hold
20.66%
Upside
Reiterated
02/27/26
Analysts Conflicted on These Healthcare Names: Arcutis Biotherapeutics (NASDAQ: ARQT), DENTSPLY SIRONA (NASDAQ: XRAY) and Edgewise Therapeutics (NASDAQ: EWTX)
BTIG Analyst forecast on ARQT
Kambiz Yazdi
BTIG
BTIG
$31
Buy
13.35%
Upside
Reiterated
01/15/26
BTIG Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arcutis Biotherapeutics

3 Months
Douglas TsaoH.C. Wainwright
Success Rate
9/15 ratings generated profit
60%
Average Return
+10.27%
Copying Douglas Tsao's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +10.27% per trade.
1 Year
Douglas TsaoH.C. Wainwright
Success Rate
13/15 ratings generated profit
87%
Average Return
+41.52%
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +41.52% per trade.
2 Years
Douglas TsaoH.C. Wainwright
Success Rate
13/15 ratings generated profit
87%
Average Return
+43.75%
Copying Douglas Tsao's trades and holding each position for 2 Years would result in 86.67% of your transactions generating a profit, with an average return of +43.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARQT Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
1
8
9
8
2
Buy
12
8
6
7
11
Hold
1
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
16
15
15
13
In the current month, ARQT has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ARQT average Analyst price target in the past 3 months is 36.57.
Each month's total comprises the sum of three months' worth of ratings.

ARQT Financial Forecast

ARQT Earnings Forecast

Next quarter’s earnings estimate for ARQT is $0.17 with a range of $0.09 to $0.28. The previous quarter’s EPS was $0.11. ARQT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ARQT has Performed in-line its overall industry.
Next quarter’s earnings estimate for ARQT is $0.17 with a range of $0.09 to $0.28. The previous quarter’s EPS was $0.11. ARQT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ARQT has Performed in-line its overall industry.

ARQT Sales Forecast

Next quarter’s sales forecast for ARQT is $141.02M with a range of $137.00M to $146.00M. The previous quarter’s sales results were $129.86M. ARQT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ARQT has Performed in-line its overall industry.
Next quarter’s sales forecast for ARQT is $141.02M with a range of $137.00M to $146.00M. The previous quarter’s sales results were $129.86M. ARQT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ARQT has Performed in-line its overall industry.

ARQT Stock Forecast FAQ

What is ARQT’s average 12-month price target, according to analysts?
Based on analyst ratings, Arcutis Biotherapeutics Inc’s 12-month average price target is 36.57.
    What is ARQT’s upside potential, based on the analysts’ average price target?
    Arcutis Biotherapeutics Inc has 33.72% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ARQT a Buy, Sell or Hold?
          Arcutis Biotherapeutics Inc has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Arcutis Biotherapeutics Inc’s price target?
            The average price target for Arcutis Biotherapeutics Inc is 36.57. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $40.00 ,the lowest forecast is $34.00. The average price target represents 33.72% Increase from the current price of $27.35.
              What do analysts say about Arcutis Biotherapeutics Inc?
              Arcutis Biotherapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of ARQT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.